Vectura Sustainability Profile
Vectura Group plc, headquartered in Great Britain, is a leading player in the pharmaceutical industry, specialising in the development of inhalation products and drug delivery solutions. Founded in 1997, Vectura has achieved significant milestones, including partnerships with major pharmaceutical companies to enhance respiratory therapies. The company focuses on innovative formulations and device technologies, particularly for asthma and chronic obstructive pulmonary disease (COPD). Vectura's unique approach combines expertise in inhalation science with advanced manufacturing capabilities, positioning it as a trusted partner in the respiratory market. With a strong presence in Europe and North America, Vectura has established itself as a key contributor to improving patient outcomes through its core products and services. Its commitment to research and development continues to drive its success and market leadership in the inhalation therapeutics sector.
DitchCarbon Score
How does Vectura's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vectura's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vectura's reported carbon emissions
In 2023, Vectura reported total carbon emissions of approximately 14,578,000 kg CO2e, with the majority, about 13,983,000 kg CO2e, classified under Scope 3 emissions. The company's Scope 1 and 2 emissions amounted to approximately 595,000 kg CO2e. This represents a slight increase from 2022, when total emissions were about 14,385,000 kg CO2e, with Scope 3 emissions at approximately 13,981,000 kg CO2e and Scope 1 and 2 emissions at around 404,000 kg CO2e. Vectura's emissions data is cascaded from its parent company, Vectura Group plc, reflecting a corporate family relationship. However, the company has not set specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction targets indicates a need for further development in their sustainability strategy. Overall, Vectura's emissions profile highlights the significant impact of Scope 3 emissions, which are often the most challenging to manage, underscoring the importance of comprehensive climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2017 | 2018 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 142,000 | 0,000,000 | 0,000,000 | - | - |
| Scope 2 | 1,272,000 | 0,000,000 | 0,000,000 | - | - |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Vectura's Industry?
How Carbon Intensive is Vectura's Location?
Vectura's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vectura has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
